Nifty
:
14677.80
Sensex
:
48732.55
-18.70 (-0.13%)
41.75 (0.09%)
Nifty
Sensex
:
:
14677.80
48732.55
-18.70 (-0.13%)
41.75 (0.09%)

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
45/99

BSE: 524816 | NSE: NATCOPHARM

NSE BSE
927.45
14-May-2021
  • Open
  • High
  • Low
  • Previous Close
  •  934.00
  •  934.00
  •  919.35
  •  924.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  406125
  •  3767.25
  •  996.00
  •  571.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,926.42
  • 35.12
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,176.32
  • 0.73%
  • 4.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.87%
  • 1.64%
  • 15.66%
  • FII
  • DII
  • Others
  • 16.35%
  • 15.38%
  • 2.10%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.34
  • 10.91
  • -4.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.46
  • 16.40
  • -8.90

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.02
  • 24.01
  • -12.85

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.28
  • 26.18
  • 20.78

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.39
  • 5.25
  • 3.56

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.59
  • 19.98
  • 15.57

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
355.20
482.20
-26.34%
802.20
485.70
65.16%
563.40
492.30
14.44%
454.80
455.70
-0.20%
Expenses
272.70
353.50
-22.86%
525.80
351.40
49.63%
392.30
301.00
30.33%
326.50
307.40
6.21%
EBITDA
82.50
128.70
-35.90%
276.40
134.30
105.81%
171.10
191.30
-10.56%
128.30
148.30
-13.49%
EBIDTM
23.23%
26.69%
34.46%
27.65%
30.37%
38.86%
28.21%
32.54%
Other Income
30.80
30.80
0.00%
25.70
33.20
-22.59%
18.70
21.00
-10.95%
22.40
31.00
-27.74%
Interest
3.40
5.30
-35.85%
2.70
6.20
-56.45%
3.70
6.50
-43.08%
3.50
5.20
-32.69%
Depreciation
29.80
25.40
17.32%
28.70
21.90
31.05%
28.00
22.00
27.27%
30.50
21.70
40.55%
PBT
80.10
128.80
-37.81%
270.70
139.40
94.19%
158.10
183.80
-13.98%
116.70
152.40
-23.43%
Tax
16.70
24.40
-31.56%
66.80
21.70
207.83%
36.00
41.00
-12.20%
23.50
32.00
-26.56%
PAT
63.40
104.40
-39.27%
203.90
117.70
73.24%
122.10
142.80
-14.50%
93.20
120.40
-22.59%
PATM
17.85%
21.65%
25.42%
24.23%
21.67%
29.01%
20.49%
26.42%
EPS
3.45
5.74
-39.90%
11.12
6.54
70.03%
6.75
7.87
-14.23%
5.17
6.62
-21.90%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
2,175.60
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
523.72
459.68
Net Sales Growth
13.55%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
26.12%
13.93%
 
Cost Of Goods Sold
551.80
354.40
332.70
411.10
599.10
341.10
242.37
233.23
242.80
203.08
186.08
Gross Profit
1,623.80
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
417.73
320.64
273.60
GP Margin
74.64%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
61.22%
59.52%
Total Expenditure
1,517.30
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
414.38
369.11
Power & Fuel Cost
-
62.40
59.60
56.20
50.50
43.70
43.24
44.77
38.75
26.88
21.41
% Of Sales
-
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
5.13%
4.66%
Employee Cost
-
375.00
355.90
325.60
243.20
189.60
136.92
112.77
102.29
80.05
66.39
% Of Sales
-
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
15.28%
14.44%
Manufacturing Exp.
-
243.30
276.40
182.60
141.20
105.20
73.04
76.57
65.10
43.32
40.18
% Of Sales
-
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
8.27%
8.74%
General & Admin Exp.
-
132.80
126.40
105.50
88.10
73.40
63.66
56.21
39.49
32.37
27.32
% Of Sales
-
6.93%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
6.18%
5.94%
Selling & Distn. Exp.
-
98.10
90.00
136.90
143.20
91.60
37.36
26.16
14.82
19.02
13.24
% Of Sales
-
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
3.63%
2.88%
Miscellaneous Exp.
-
66.40
58.70
38.50
71.50
24.10
15.31
9.85
7.36
9.66
13.24
% Of Sales
-
3.47%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
1.84%
3.15%
EBITDA
658.30
582.60
794.80
928.40
683.40
272.60
213.38
179.33
149.93
109.34
90.57
EBITDA Margin
30.26%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
20.88%
19.70%
Other Income
97.60
107.40
130.20
40.40
13.90
9.90
14.91
16.71
12.41
9.14
4.64
Interest
13.30
21.50
19.30
15.40
18.50
22.90
31.68
36.62
26.31
23.04
14.20
Depreciation
117.00
99.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
15.91
15.88
PBT
625.60
568.70
824.70
887.20
624.40
208.60
149.34
128.98
113.90
79.54
65.12
Tax
143.00
110.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
21.07
13.21
Tax Rate
22.86%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
26.49%
20.29%
PAT
482.60
460.80
644.40
696.20
486.00
157.10
134.62
102.74
71.87
59.61
53.51
PAT before Minority Interest
482.00
458.10
642.40
695.20
484.90
155.80
130.27
98.11
65.88
58.47
51.91
Minority Interest
-0.60
2.70
2.00
1.00
1.10
1.30
4.35
4.63
5.99
1.14
1.60
PAT Margin
22.18%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
11.38%
11.64%
PAT Growth
-0.56%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
20.57%
11.40%
 
EPS
26.47
25.28
35.35
38.19
26.66
8.62
7.38
5.64
3.94
3.27
2.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
473.63
352.43
Share Capital
36.40
36.50
36.90
34.90
34.80
33.23
33.07
31.37
31.15
28.15
Total Reserves
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
442.49
324.29
Non-Current Liabilities
117.80
83.40
47.10
37.70
28.00
119.23
150.67
191.46
171.34
160.44
Secured Loans
0.00
0.00
0.00
0.00
0.00
94.03
92.20
135.62
133.88
125.21
Unsecured Loans
0.90
0.00
0.00
0.00
0.00
2.99
3.28
2.21
0.22
0.22
Long Term Provisions
90.20
71.00
32.40
21.90
12.50
9.50
11.09
8.62
6.59
8.67
Current Liabilities
685.30
728.70
592.00
626.50
493.10
413.74
312.28
344.87
259.35
193.38
Trade Payables
255.40
217.00
269.10
262.70
275.60
125.30
109.79
105.85
92.36
76.60
Other Current Liabilities
95.90
109.80
133.40
127.10
114.20
118.56
102.18
90.21
81.91
43.86
Short Term Borrowings
315.00
386.30
173.20
221.60
98.40
168.54
98.63
147.74
81.64
72.02
Short Term Provisions
19.00
15.60
16.30
15.10
4.90
1.33
1.69
1.07
3.44
0.91
Total Liabilities
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
905.20
707.31
Net Block
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
319.56
270.16
Gross Block
2,148.60
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
726.97
440.33
374.37
Accumulated Depreciation
564.20
467.30
389.00
325.70
273.20
225.82
171.11
140.57
117.34
104.21
Non Current Assets
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
612.42
460.37
Capital Work in Progress
518.00
637.60
480.00
336.30
211.80
128.96
123.78
105.84
164.43
75.98
Non Current Investment
83.60
19.90
8.10
0.10
0.10
1.57
1.57
1.54
61.79
61.79
Long Term Loans & Adv.
72.00
62.80
75.40
60.40
62.10
57.03
54.25
57.20
66.22
51.49
Other Non Current Assets
4.20
8.40
2.30
0.50
0.60
3.54
3.24
2.61
0.42
0.96
Current Assets
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
292.79
246.95
Current Investments
28.70
148.70
68.40
32.10
22.10
0.12
0.32
0.81
0.74
0.82
Inventories
558.00
529.00
438.40
348.90
357.30
220.00
181.12
146.02
110.39
102.23
Sundry Debtors
551.30
506.20
637.50
475.20
261.60
192.43
118.80
129.71
94.69
70.98
Cash & Bank
66.00
279.50
183.70
35.80
45.20
13.36
11.05
10.78
36.63
32.37
Other Current Assets
1,121.60
107.40
53.20
25.80
150.80
57.06
56.85
43.14
50.34
40.55
Short Term Loans & Adv.
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
38.85
41.84
36.73
Net Current Assets
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
33.44
53.56
Total Assets
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42
905.21
707.32

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
417.30
668.80
463.60
345.80
112.20
92.67
144.03
61.19
64.94
36.99
PBT
568.70
824.70
887.20
624.40
208.60
134.22
128.98
102.32
79.54
65.12
Adjustment
54.00
14.30
75.60
100.20
90.50
68.14
65.72
48.87
36.97
38.87
Changes in Working Capital
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
-27.97
-48.50
Cash after chg. in Working capital
525.10
847.60
668.20
471.60
158.40
116.41
178.58
83.80
88.54
55.49
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
-23.60
-18.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
-126.94
-88.78
Net Fixed Assets
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
-151.51
-71.49
Net Investments
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
-3.71
8.04
Others
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
28.28
-25.33
Cash from Financing Activity
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
62.78
77.10
Net Cash Inflow / Outflow
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
0.78
25.31
Opening Cash & Equivalents
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
31.70
6.53
Closing Cash & Equivalent
19.80
28.30
21.70
23.50
-74.20
12.44
10.22
9.95
34.64
31.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
206.04
189.49
165.22
93.63
73.91
50.91
219.48
170.06
152.06
125.21
ROA
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
7.25%
8.23%
ROE
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
14.16%
15.77%
ROCE
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
15.72%
15.90%
Fixed Asset Turnover
1.07
1.47
1.72
1.93
1.23
0.95
0.96
1.14
1.30
1.27
Receivable days
93.77
91.36
92.22
65.12
70.27
67.76
60.90
61.30
56.98
50.31
Inventory Days
96.38
77.28
65.25
62.41
89.35
87.33
80.17
70.04
73.13
70.50
Payable days
65.96
72.53
81.42
78.30
85.42
73.36
74.09
73.36
79.03
83.93
Cash Conversion Cycle
124.19
96.11
76.05
49.23
74.21
81.73
66.99
57.98
51.07
36.89
Total Debt/Equity
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
0.55
0.62
Interest Cover
27.45
43.73
58.61
34.75
10.11
5.24
4.52
4.89
4.45
5.59

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Natco Pharma gets emergency use approval from CDSCO for Baricitinib tablets for Covid-19 treatment
    3rd May 2021, 09:18 AM

    The company is ready to launch the product this week, so as to make the product available to suffering patients across India

    Read More
  • Natco Pharma applies to CDSCO for Phase-III clinical trial of Molnupiravir Capsules for Covid-19 treatment
    26th Apr 2021, 09:32 AM

    Pre-clinical data has shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication

    Read More
  • Natco Pharma's distribution partner gets tentative approval for Ibrutinib tablets
    12th Apr 2021, 09:19 AM

    As per industry sales data, Imbruvica had generated annual sales of $3.7 billion during the twelve months period ending December 2020 in the US market

    Read More
  • Natco Pharma gets nod to acquire 0.96% stake in NATCO Pharma Canada Inc.
    26th Mar 2021, 12:15 PM

    Post acquisition NATCO Pharma Canada Inc.,will become wholly owned subsidiary of the company

    Read More
  • Natco Pharma forays into Pheromone based technology for IPM
    15th Mar 2021, 14:04 PM

    During Kharif 2021, NATCO plans to launch its first Green Label Pheromone product for Effective Management of Pink Bollworm (PBW) in cotton crop, under its brand NATMATE PBW

    Read More
  • Natco Pharma’s marketing partner gets approval for Everolimus Tablets
    8th Mar 2021, 10:57 AM

    The above strengths of Everolimus are indicated in the treatment of breast cancer and a few other types of cancers

    Read More
  • Natco Pharma launches Brivaracetam tablets in India
    26th Feb 2021, 11:57 AM

    Brivaracetam is indicated towards treatment of epilepsy

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.